U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Gd.3O
Molecular Weight 362.5
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GADOLINIUM OXIDE

SMILES

[O--].[O--].[O--].[Gd+3].[Gd+3]

InChI

InChIKey=CMIHHWBVHJVIGI-UHFFFAOYSA-N
InChI=1S/2Gd.3O/q2*+3;3*-2

HIDE SMILES / InChI

Molecular Formula Gd
Molecular Weight 157.25
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/

DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.

CNS Activity

Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27169
Gene ID: 5444.0
Gene Symbol: PON1
Target Organism: Homo sapiens (Human)
105.0 mM [Ki]
Target ID: P52209
Gene ID: 5226.0
Gene Symbol: PGD
Target Organism: Homo sapiens (Human)
73.0 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DOTAREM

Approved Use

Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Launch Date

2013
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

2011
PubMed

PubMed

TitleDatePubMed
Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism.
1994 Sep
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors.
1997 May
Aluminum is a weak agonist for the calcium-sensing receptor.
1999 May
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations.
2002 Jun 1
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
Gadolinium-containing contrast media for radiographic examinations: a position paper.
2002 Oct
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium.
2004 May
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
2005 Apr 20
Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C.
2006 Apr 28
Renal safety of gadolinium-based contrast agent for ionizing radiation imaging.
2006 Jul
Gadolinium-based contrast media for multi-detector row spiral CT pulmonary angiography in patients with renal insufficiency.
2006 Mar
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008 Jul
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency.
2009 Dec
Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity.
2010 Aug
Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
2010 Nov
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes.
2011 Feb 18
Heavy metal cations permeate the TRPV6 epithelial cation channel.
2011 Jan
Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.
2015 Dec
Patents

Sample Use Guides

Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight. Administer as an intravenous bolus injection. Follow injection with a normal saline flush.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:37:21 GMT 2023
Edited
by admin
on Fri Dec 15 18:37:21 GMT 2023
Record UNII
5480D0NHLJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GADOLINIUM OXIDE
II   WHO-DD  
Common Name English
Gadolinium oxide [WHO-DD]
Common Name English
GADOLINIA
Common Name English
GADOLINIUM TRIOXIDE
Common Name English
GADOLINIUM SESQUIOXIDE
Common Name English
GADOLINIUM(III) OXIDE
Common Name English
DIGADOLINIUM TRIOXIDE
Common Name English
GADOLINIUM OXIDE (GD2O3)
Common Name English
Code System Code Type Description
CAS
12064-62-9
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
EVMPD
SUB35119
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID4051613
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
PUBCHEM
159427
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
MESH
C030581
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
WIKIPEDIA
GADOLINIUM(III) OXIDE
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
DAILYMED
5480D0NHLJ
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
RXCUI
1311118
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
235-060-9
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
FDA UNII
5480D0NHLJ
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
SMS_ID
100000128280
Created by admin on Fri Dec 15 18:37:21 GMT 2023 , Edited by admin on Fri Dec 15 18:37:21 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY